CDKN2A and head and neck squamous cell carcinoma: Even though there are inherent limitations in our approach of mapping the immune profiles in p16+ HNSSC and p16- HNSCC, the results may add some critical information to better understand the background of the differences in treatment outcomes seen in the two groups.